Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 15, 2011
October 27, 2022
08a2bd54-10f9-493d-9a2b-e5dd0c222f5b
Related Documents
Individual Patient Expanded Access Applications: Form FDA 3926
Guidance DocumentOctober 3, 2017Center for Drug Evaluation and Research
Pre-Launch Activities Importation Requests (PLAIR): Guidance for Industry
Guidance DocumentMarch 1, 2022Center for Drug Evaluation and Research
Tropical Disease Priority Review Vouchers
Guidance DocumentOctober 6, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox